(Q37899929)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Xavier Calvet

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

11 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

604-617

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21745241%20AND%20SRC:MED&resulttype=core&format=json

Clinical practice. Helicobacter pylori infection

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

[Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential regimens for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

New concepts of resistance in the treatment of Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

High Helicobacter pylori numbers are associated with low eradication rate after triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

The importance of efflux pumps in bacterial antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

H. pylori treatment: new wine in old bottles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Smoking increases the treatment failure for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Efficacy of Helicobacter pylori eradication therapies: a single centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential therapy for H. pylori: an 'aberrant' therapy ready for general use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04770.X